›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:HTG EdgeSeq Oncology Biomarker Panel (OBP)
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
HTG Molecular DiagnosticsType:
Laboratory Developed Test
Related tests:
Evidence Level:
Resistant: B - Late Trials
[CCNE1 overexpression-Breast Cancer-palbociclib]
Source:
Title:
Prognostic and predictive role of RBsig and CCNE1/RB1 gene-expression signatures in patients with advanced breast cancer treated with palbociclib in combination with endocrine therapy in the PALOMA-2 and 3 trials
Published date:
11/22/2022
Excerpt:
...in PALOMA- 3 patients with CCNE1/RB1 high tumors treated in the palbociclib arm showed a significantly worse outcome compared to those with CCNE1/RB1 low but this effect was not observed in those treated in the control arm [HR 1.6 (95% CI 1.1- 2.5) p= 0.03 for palbociclib arm; HR 1.2 (95% CI 0.7, 1.9) p=0.5 for control arm].
Trial ID:
Evidence Level:
Resistant: B - Late Trials
[RB1 overexpression-Breast Cancer-palbociclib]
Source:
Title:
Prognostic and predictive role of RBsig and CCNE1/RB1 gene-expression signatures in patients with advanced breast cancer treated with palbociclib in combination with endocrine therapy in the PALOMA-2 and 3 trials
Published date:
11/22/2022
Excerpt:
...in PALOMA- 3 patients with CCNE1/RB1 high tumors treated in the palbociclib arm showed a significantly worse outcome compared to those with CCNE1/RB1 low but this effect was not observed in those treated in the control arm [HR 1.6 (95% CI 1.1- 2.5) p= 0.03 for palbociclib arm; HR 1.2 (95% CI 0.7, 1.9) p=0.5 for control arm].
Trial ID:
